Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00021151 · ClinicalTrials.gov registry record · NA

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

A NA study of Leukemia, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
2
Enrollment target
1
Study location

NCT00021151 is a NA study of Leukemia that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 2 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00021151, a NA study of Leukemia, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
2 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Compassionate use refers to providing a drug to a patient on humanitarian grounds before the drug has received official approval. PURPOSE: Compassionate use of Campath-1H in treating patients who have refractory prolymphocytic leukemia or chronic lymphocytic leukemia.

Conditions Studied

Interventions

  • BIOLOGICAL alemtuzumab

Study Locations (1)

Ohio

  • Ireland Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2000-01
Est. Completion 2002-05
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT00021151

The ClinicalTrials.gov registry entry for NCT00021151 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (100% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which alemtuzumab is the first listed.

NCT00021151 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00021151 about?

NCT00021151 is a clinical study titled "Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Compassionate use refers to providing a drug to a patient on humanitarian grounds before the drug has received official approval. PURPOSE: Compass...

What is the current status of trial NCT00021151?

This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2000-01. Estimated completion is 2002-05.

What conditions does trial NCT00021151 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT00021151?

The interventions under investigation include: alemtuzumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00021151?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00021151 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.